Vincent Forlenza Net Worth

The estimated Net Worth of Vincent A Forlenza is at least $74.3 Million dollars as of 28 January 2020. Mr. Forlenza owns over 38,362 units of Becton Dickinson & Co stock worth over $57,774,244 and over the last 21 years he sold BDX stock worth over $529,546. In addition, he makes $16,014,600 as Executive Chairman of the Board at Becton Dickinson & Co.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Forlenza BDX stock SEC Form 4 insiders trading

Vincent has made over 51 trades of the Becton Dickinson & Co stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 38,362 units of BDX stock worth $2,766,667 on 28 January 2020.

The largest trade he's ever made was exercising 105,225 units of Becton Dickinson & Co stock on 24 February 2004 worth over $2,155,008. On average, Vincent trades about 11,159 units every 38 days since 2003. As of 28 January 2020 he still owns at least 247,226 units of Becton Dickinson & Co stock.

You can see the complete history of Mr. Forlenza stock trades at the bottom of the page.

Vincent Forlenza biography

Vincent A. Forlenza serves as Executive Chairman of the Board of the Company. He became BD’s Chairman in 2012 and was elected its Chief Executive Officer in 2011. He also served as BD’s President from 2009 to April 2017, and as its Chief Operating Officer from July 2010 to October 2011. He is a director of the Advanced Medical Technology Association (AdvaMed), an international medical technology trade organization, a director of the Quest Autism Foundation, and a member of the Board of Trustees of The Valley Health System. Mr. Forlenza also is a director of Moody’s Corporation. Mr. Forlenza has been with BD for over 39 years in a number of different capacities, including strategic planning, business development, research and development and general management, and in overseas roles. Mr. Forlenza brings to the Board extensive business and industry experience, and provides the Board with a unique perspective on BD’s strategy and operations, particularly in the area of new product development.

What is the salary of Vincent Forlenza?

As the Executive Chairman of the Board of Becton Dickinson & Co, the total compensation of Vincent Forlenza at Becton Dickinson & Co is $16,014,600. There are no executives at Becton Dickinson & Co getting paid more.

How old is Vincent Forlenza?

Vincent Forlenza is 66, he's been the Executive Chairman of the Board of Becton Dickinson & Co since 2020. There are 5 older and 29 younger executives at Becton Dickinson & Co. The oldest executive at Becton Dickinson & Co. is Marshall Larsen, 71, who is the Lead Independent Director.

Insiders trading at Becton Dickinson & Co

Over the last 22 years, insiders at Becton Dickinson & Co have traded over $106,782,599 worth of Becton Dickinson & Co stock and bought 23,860 units worth $1,771,828 . The most active insiders traders include Edward J Ludwig, William M Brown und Vincent A Forlenza. On average, Becton Dickinson & Co executives and independent directors trade stock every 20 days with the average trade being worth of $4,349,205. The most recent stock trade was executed by Roland Goette on 14 August 2024, trading 5,295 units of BDX stock currently worth $701,799.

What does Becton Dickinson & Co do?

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.

Complete history of Mr. Forlenza stock trades at Becton Dickinson & Co und Moody`s

Becton Dickinson & Co executives and stock owners

Becton Dickinson & Co executives and other stock owners filed with the SEC include:

• Vincent Forlenza,
  Executive Chairman of the Board
• Patrick Kaltenbach,
  Executive Vice President, President - Life Sciences
• Thomas Polen,
  President, Chief Executive Officer, Chief Operating Officer, Director
• Christopher Reidy,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer
• Alberto Mas,
  Executive Vice President, President - Medical Segment
• Thomas E. Polen Jr.,
  Pres, CEO & Chairman
• Samrat Khichi,
  Executive Vice President - Public Policy and Regulatory Affairs
• Alexandre Conroy,
  Executive Vice President, Chief Integrated Supply Chain Officer
• Vincent A. Forlenza,
  Exec. Chairman
• Samrat S. Khichi,
  Exec. VP of Regulatory & Gov. Affairs and Gen. Counsel
• Alberto Mas,
  Exec. VP & Pres of the Medical Segment
• Samrat S. Khichi Esq.,
  Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel
• Christopher R. Reidy,
  Exec. VP, CFO & Chief Admin. Officer
• Simon D. Campion,
  Exec. VP & Pres of Interventional Segment
• Christopher DelOrefice,
  Exec. VP & CFO
• Marshall Larsen,
  Lead Independent Director
• Bertram Scott,
  Independent Director
• Claire Fraser,
  Independent Director
• Christopher Jones,
  Independent Director
• Catherine Burzik,
  Independent Director
• Claire Pomeroy,
  Independent Director
• Timothy Ring,
  Independent Director
• Rebecca Rimel,
  Independent Director
• David Melcher,
  Independent Director
• Jeffrey Henderson,
  Independent Director
• R. Andrew Eckert,
  Independent Director
• John DeFord,
  Executive Vice President, Chief Technology Officer
• James Lim,
  Executive Vice President, President, Greater Asia
• Thomas Spoerel,
  Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller
• Monique Dolecki,
  Investor Relations Contact Officer
• Charles Bodner,
  Senior Vice President, Corporate Finance
• Roland Goette,
  Executive Vice President, President - EMEA
• Simon Campion,
  Executive Vice President and President, BD Interventional Segment
• Betty Larson,
  Executive Vice President- Human Resources, Chief Human Resources
• Denise Fleming,
  Exec. VP of Technology & Global Services and Chief Information Officer
• Francesca M. DeMartino,
  Sr. VP of Investor Relations
• Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.,
  Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board
• Troy Kirkpatrick,
  VP of PR
• Elizabeth McCombs,
  Exec. VP & Chief Technology Officer
• Michelle Quinn,
  Sr. VP and Chief Ethics & Compliance Officer
• Jerry Flasz,
  Exec. VP of Global Services & Chief Information Officer
• Dr. John A. DeFord,
  Exec. VP of R&D and CTO
• Thomas J. Spoerel,
  Sr. VP, Controller & Chief Accounting Officer
• Joanne Waldstreicher,
  Director
• Gary A Mecklenburg,
  Director
• John E Gallagher,
  VP, Corp Finance and Treasurer
• Linda M Tharby,
  Segment Pres. Life Sciences
• Wilard J Jr Overlock,
  Director
• Nabil Shabshab,
  Senior Vice President
• Jeffrey S Sherman,
  VP and General Counsel
• Basil Anderson,
  Director
• Ellen R Strahlman,
  Senior Vice President
• James F Orr,
  Director
• William A Tozzi,
  VP and Controller
• Gary M Cohen,
  President - BD Medical Systems
• Stephen Sichak,
  Senior Vice President
• Henry P Jr Becton,
  Director
• Carrie L Byington,
  Director
• Edward Degraan,
  Director
• William A Kozy,
  Pres - BD CLS and Cmpy Oper
• Alfred Sommer,
  Director
• David Shan,
  EVP and Chief ISC Officer
• Shana Carol Neal,
  EVP and Chief People Officer
• John P Groetelaars,
  EVP
• James W Borzi,
  EVP & Chief Supply Chain Offcr
• Suketu Upadhyay,
  Senior VP and Controller
• Adel Mahmoud,
  Director
• Jerome V Hurwitz,
  Senior Vice President
• Donna M Boles,
  Sr. Exec VP - Human Resources
• David V Elkins,
  Executive VP and CFO
• David T Durack,
  Senior Vice President
• William E. Rhodes,
  Senior Vice President
• Joseph Mercurio,
  VP and Corporate Controller
• Patricia B Shrader,
  Senior Vice President
• Scott P Bruder,
  SrVP; Chief Technology Officer
• Cathy E. Minehan,
  Director
• Margeretha Af Ugglas,
  Director
• Edward J Ludwig,
  Chairman, President and CEO
• James E Perrella,
  Director
• Alfred John Hanson,
  Executive Vice President
• John R Considine,
  Executive VP and CFO
• Jean Marc Dageville,
  VP - Human Resources
• Harry N Beaty,
  Director
• Frank Albert Olson,
  Director
• Bridget M Healy,
  VP, Gen Counsel and Secy
• Christopher Del Orefice,
  EVP & Chief Financial Officer
• Antoine C Ezell,
  EVP, President NA & CMO
• David Hickey,
  EVP & President, Life Sciences
• William M Brown,
  Director
• Rishi Grover,
  EVP and Chief ISC Officer
• Michael David Garrison,
  EVP & President Medical
• Richard Byrd,
  EVP & President Interventional
• Pavan Kumar Mocherla,
  EVP & President Greater Asia
• Michael Feld,
  EVP & President, Life Sciences